Guidance Archives - Page 612 of 637

3 minute read

Tesla Shareholders Approve 3-For-1 Stock Split — Elon Musk Shares Cybertruck Update, Teases New Factory

August 4, 9:54 PM

Tesla Inc (NASDAQ: TSLA) held its annual shareholder meeting at its manufacturing facility in Austin, Texas on Thursday evening. Most of the 13 board recommendations were passed by shareholders, while CEO Elon Musk charted the electric vehicle maker's progress.

ORCL

1 minute read

Phillips Edison & Company Sees FY22 FFO $2.09-$2.15 Vs $2.07-$2.13 Prior

By Benzinga Newsdesk

August 4, 7:27 PM

Updated Full Year 2022 Guidance Prior Full Year 2022 Guidance Net income per share $0.34 - $0.40 $0.29 - $0.35 Nareit FFO per

PECO

1 minute read

Quantum Corporation Sees Q2 2023 Revenue $95M +/-$4M Vs $94.77M Est; Sees Adj. EPS $(0.02) +/- $0.01 Vs $(0.02) Est

By Benzinga Newsdesk

August 4, 7:24 PM

Outlook Based on currently committed supply, the Company expects the following guidance range for the second fiscal quarter of 2023: Revenues of $95 million, plus or minus $4 million Non-GAAP

QMCO

1 minute read

Genpact Narrows Guidance Sees FY22 Revenue $4.32B-$4.37B Vs $4.27B Est

By Benzinga Newsdesk

August 4, 5:29 PM

Full Year 2022 Outlook Genpact now expects: Total revenue in the range of $4.32 billion to $4.37 billion, up 7.5% to 9.0%, or 9.5% to 11.0% on a constant

2 minute read

‘I Had More Kids In Q2 Than They Made Cars!’ Said Elon Musk About This Tesla Rival

By AJ Fabino

August 4, 5:29 PM

The Tesla Inc (NASDAQ: TSLA) CEO and richest man in the world Elon Musk isn’t shy of trolling others on his Twitter Inc (NYSE: TWTR) account.

LCID

2 minute read

Rocket Companies Stock Fails To Launch Following Q2 Revenue, EPS Miss

By Adam Eckert

August 4, 4:39 PM

Rocket Companies Inc (NYSE: RKT) announced its second-quarter financial results after the close. Here's a rundown of the results.

RKT

1 minute read

Maravai LifeSciences Lowers FY2022 Adj EPS Guidance from $1.74-1.90 to $1.70-1.80; Lowers FY2022 Sales Guidance from $920.00M-960.00M to $880.00M-910.00M

By Benzinga Newsdesk

August 4, 4:29 PM

Maravai LifeSciences (NASDAQ:MRVI) lowers FY2022 Adj EPS guidance from $1.74-1.90 to $1.70-1.80. Lowers FY2022 sales outlook from $920.00 million-960.00 million to $880.00 million-910.00 million.

MRVI

1 minute read

Atlassian Corporation Sees Q1 Adj EPS $0.37-0.38 vs $0.37 Est; Sees Sales $795.000M-810.000M vs $773.00M Est

By Benzinga Newsdesk

August 4, 4:17 PM

Atlassian Corporation (NASDAQ:TEAM) is looking for Q1 Adj EPS of $0.37-0.38 vs $0.37 analyst estimate. seessales of $795.000 million-810.000 million vs $773.00 million estimate.

TEAM

1 minute read

TripAdvisor Sees Q3 2022 Consolidated Net Revenue Higher Than 2019 By Low- To-Mid Single Digit Percentage Points

By Benzinga Newsdesk

August 4, 4:08 PM

We expect a seasonal step down in consolidated adjusted EBITDA margin in Q4 versus Q3. In addition, in 2H we expect to partly reinvest the Q2 2022 COVID-19 related benefit in TheFork.

TRIP

1 minute read

Amgen Affirms FY2022 Adj EPS Guidance from $17.00-18.00 to $17.00-18.00; Narrows FY2022 Sales Guidance from $25.40B-26.50B to $25.50B-26.40B

By Benzinga Newsdesk

August 4, 4:05 PM

Amgen (NASDAQ:AMGN) affirms FY2022 Adj EPS guidance from $17.00-18.00 to $17.00-18.00. Narrows FY2022 sales outlook from $25.40 billion-26.50 billion to $25.50 billion-26.40 billion.

AMGN